Latasopt 2.5 ml 0.005% eye drops
- $41.00
The instruction for medical use
medicine
LATASOPT
the Trade name
of Latasopt
the International unlicensed
name Latanoprost Lekarstvennaya a form
Eye drops of 0.005%
Structure
of 1 ml of drug contains
active agent: latanoprost 0.05 mg.
excipients: dinatrium hydrophosphate dodecahydrate, sodium dihydrophosphate a dihydrate, sodium chloride, a benzalkoniya chloride, water purified.
The description
Colourless transparent solution
Pharmacotherapeutic group
Protivoglaukomny means
the Code of automatic telephone exchange SO1EE01
the Pharmacological
Pharmacokinetics Well properties gets through a cornea, at the same time there is a hydrolysis of the latanoprost to biologically active form – latanoprost acids.
The maximum concentration in watery moisture is reached approximately in the 2nd hour after topical administration.
It is distributed, first of all, in a front segment of an eye, in a conjunctiva and centuries. Only the insignificant amount of drug reaches a back segment of an eye. In eye tissues latanoprost acid is practically not metabolized, metabolism happens, mainly, in a liver. Elimination half-life makes 17 minutes. The main metabolites – 1.2-dinor- and 1,2,3,4-tetranor-metabolites do not possess or have weak biological activity and are removed generally with urine.
A pharmacodynamics
of Latasopt – protivoglaukomny means. Active ingredient of drug - latonoprost – is an analog of F2a prostaglandin and selection FP agonist of prescriptions. Reduces intraocular pressure by increase in outflow of watery moisture and has protivoglaukomny effect.
The main mechanism of action Latasopta is connected with increase in uveoskleralny outflow. Has no reliable impact on
products of watery moisture and does not influence a blood-ocular barrier. Decrease in intraocular pressure begins in 3-4 hours after administration of drug, the maximum effect is noted in 8-12 hours, action continues within not less than 24 hours.
The indication to use
- the increased intraocular pressure at patients with an open
angle glaucoma and the raised intraocular tension, including at
tolerance to other means lowering intraocular pressure
or their insufficient efficiency
the Route of administration and doses
Only for topical administration.
Drug is dug in in a conjunctival sac of the affected eye on 1 drop of 1 times a day, in the evening.
In case of the admission of a dose the following use of drug is carried out in the usual mode (the dose is not doubled).
At simultaneous use of other local ophthalmologic means the interval between instillations has to be not less than 10 minutes.
Side effects
Often
- irritation of an eye (burning, an itching, feeling of a foreign body after instillation) and also darkening, a thickening and lengthening of eyelashes
Is rare
- conjunctival hyperaemia, tranzitorny fine-molded epithelial erosion, blefarita, increase in pigmentation of an iris, morbidity of eyes Very seldom
- skin rash, hypostases a century
- darkening of an eyelid skin
- hypostasis and erosion of a cornea
- irites, uveites
- macular hypostasis including cystous (mainly, at patients with
an aphakia, a pseudo-aphakia, damage of the back capsule of a crystalline lens or with
risk factors of developing macular hypostasis)
Contraindications
- hypersensitivity to drug components
- the children's age up to 18 years
Medicinal interactions
of Latasopt pharmaceutical is incompatible with timerosaly as perhaps precipitation.
Drug can be also used along with the means lowering the intraocular pressure (Timololum, adrenomimetik, acetazoleamide).
Gradual change of color of eyes due to increase in quantity of a brown pigment in an iris can cause special indications of Latasopt. This effect comes to light mainly at patients from the iris mixed by coloring that is explained by increase in content of melanin in stromal melanocytes of an iris. At patients with evenly painted eyes of discoloration of eyes after two years of use of drug were observed very seldom. Discoloration is not followed with what - either clinical symptoms or pathological changes. After drug withdrawal the further increase in quantity of a brown pigment was not observed, however already developed discoloration can be irreversible. In the presence of a nevus or lentigo on an iris their change under the influence of therapy was not noted.
Prior to treatment of patients it is necessary to inform on a possibility of discoloration of eyes. In case of intensive change of pigmentation of eyes the treatment can be stopped. Treatment only of one eye can result in constant heterochromia.
It is not necessary to apply Latasopt more often than once in day as more frequent introduction can reduce medical effect.
At active inflammatory process in an eyeball (iritis, a uveitis), an aphakia, a pseudo-aphakia with damage of the capsule of a crystalline lens it is necessary to be limited to drug use.
When using contact lenses it is necessary to remove them before burying and again to dress not earlier than in 15-20 minutes after drug instillation.
The bottle needs to be closed after each use. It is not necessary to touch with a pipette tip an eye.
Pregnancy and the period of a lactation
Latasopt's Use at pregnancy is possible only when the expected advantage for mother exceeds potential risk for a fruit.
It is necessary to use with care drug in the period of a lactation as latanoprost and its metabolites can be allocated with breast milk.
Features influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
the Drug Latasopt should be used with care to the patients who are engaged in potentially dangerous type of activity, requiring special attention and speed of psychomotor reactions.
A form of release and packing
On 2.5 ml of drug in a plastic bottle with a stopper – a dropper and the screwing-up protective cap supplied with a safety ring.
On 1 bottle together with the instruction for medical use in the state and Russian languages put in a box of cardboard.
Stores storage conditions in the place protected from light at a temperature from 2º to 8C.
After opening of a bottle to store drug at a temperature 25C and to use within 4 weeks.
To store out of children's reach!
3 years
not to apply a period of storage after an expiration date.
Prescription status
According to the prescription
the Producer
the Owner of a trademark and the certificate of registration is
the UORLD MEDITSIN company, Great Britain
Rompharm Company of S.R. L., Romania
the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products
of RK, Almaty, Turksibsky district, Suyunbaya Avenue, 222b
Bodies/ph. 8 (7272) 529090 Is made
E-mail address: www.worldmedicine.kz
medicine
LATASOPT
the Trade name
of Latasopt
the International unlicensed
name Latanoprost Lekarstvennaya a form
Eye drops of 0.005%
Structure
of 1 ml of drug contains
active agent: latanoprost 0.05 mg.
excipients: dinatrium hydrophosphate dodecahydrate, sodium dihydrophosphate a dihydrate, sodium chloride, a benzalkoniya chloride, water purified.
The description
Colourless transparent solution
Pharmacotherapeutic group
Protivoglaukomny means
the Code of automatic telephone exchange SO1EE01
the Pharmacological
Pharmacokinetics Well properties gets through a cornea, at the same time there is a hydrolysis of the latanoprost to biologically active form – latanoprost acids.
The maximum concentration in watery moisture is reached approximately in the 2nd hour after topical administration.
It is distributed, first of all, in a front segment of an eye, in a conjunctiva and centuries. Only the insignificant amount of drug reaches a back segment of an eye. In eye tissues latanoprost acid is practically not metabolized, metabolism happens, mainly, in a liver. Elimination half-life makes 17 minutes. The main metabolites – 1.2-dinor- and 1,2,3,4-tetranor-metabolites do not possess or have weak biological activity and are removed generally with urine.
A pharmacodynamics
of Latasopt – protivoglaukomny means. Active ingredient of drug - latonoprost – is an analog of F2a prostaglandin and selection FP agonist of prescriptions. Reduces intraocular pressure by increase in outflow of watery moisture and has protivoglaukomny effect.
The main mechanism of action Latasopta is connected with increase in uveoskleralny outflow. Has no reliable impact on
products of watery moisture and does not influence a blood-ocular barrier. Decrease in intraocular pressure begins in 3-4 hours after administration of drug, the maximum effect is noted in 8-12 hours, action continues within not less than 24 hours.
The indication to use
- the increased intraocular pressure at patients with an open
angle glaucoma and the raised intraocular tension, including at
tolerance to other means lowering intraocular pressure
or their insufficient efficiency
the Route of administration and doses
Only for topical administration.
Drug is dug in in a conjunctival sac of the affected eye on 1 drop of 1 times a day, in the evening.
In case of the admission of a dose the following use of drug is carried out in the usual mode (the dose is not doubled).
At simultaneous use of other local ophthalmologic means the interval between instillations has to be not less than 10 minutes.
Side effects
Often
- irritation of an eye (burning, an itching, feeling of a foreign body after instillation) and also darkening, a thickening and lengthening of eyelashes
Is rare
- conjunctival hyperaemia, tranzitorny fine-molded epithelial erosion, blefarita, increase in pigmentation of an iris, morbidity of eyes Very seldom
- skin rash, hypostases a century
- darkening of an eyelid skin
- hypostasis and erosion of a cornea
- irites, uveites
- macular hypostasis including cystous (mainly, at patients with
an aphakia, a pseudo-aphakia, damage of the back capsule of a crystalline lens or with
risk factors of developing macular hypostasis)
Contraindications
- hypersensitivity to drug components
- the children's age up to 18 years
Medicinal interactions
of Latasopt pharmaceutical is incompatible with timerosaly as perhaps precipitation.
Drug can be also used along with the means lowering the intraocular pressure (Timololum, adrenomimetik, acetazoleamide).
Gradual change of color of eyes due to increase in quantity of a brown pigment in an iris can cause special indications of Latasopt. This effect comes to light mainly at patients from the iris mixed by coloring that is explained by increase in content of melanin in stromal melanocytes of an iris. At patients with evenly painted eyes of discoloration of eyes after two years of use of drug were observed very seldom. Discoloration is not followed with what - either clinical symptoms or pathological changes. After drug withdrawal the further increase in quantity of a brown pigment was not observed, however already developed discoloration can be irreversible. In the presence of a nevus or lentigo on an iris their change under the influence of therapy was not noted.
Prior to treatment of patients it is necessary to inform on a possibility of discoloration of eyes. In case of intensive change of pigmentation of eyes the treatment can be stopped. Treatment only of one eye can result in constant heterochromia.
It is not necessary to apply Latasopt more often than once in day as more frequent introduction can reduce medical effect.
At active inflammatory process in an eyeball (iritis, a uveitis), an aphakia, a pseudo-aphakia with damage of the capsule of a crystalline lens it is necessary to be limited to drug use.
When using contact lenses it is necessary to remove them before burying and again to dress not earlier than in 15-20 minutes after drug instillation.
The bottle needs to be closed after each use. It is not necessary to touch with a pipette tip an eye.
Pregnancy and the period of a lactation
Latasopt's Use at pregnancy is possible only when the expected advantage for mother exceeds potential risk for a fruit.
It is necessary to use with care drug in the period of a lactation as latanoprost and its metabolites can be allocated with breast milk.
Features influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
the Drug Latasopt should be used with care to the patients who are engaged in potentially dangerous type of activity, requiring special attention and speed of psychomotor reactions.
A form of release and packing
On 2.5 ml of drug in a plastic bottle with a stopper – a dropper and the screwing-up protective cap supplied with a safety ring.
On 1 bottle together with the instruction for medical use in the state and Russian languages put in a box of cardboard.
Stores storage conditions in the place protected from light at a temperature from 2º to 8C.
After opening of a bottle to store drug at a temperature 25C and to use within 4 weeks.
To store out of children's reach!
3 years
not to apply a period of storage after an expiration date.
Prescription status
According to the prescription
the Producer
the Owner of a trademark and the certificate of registration is
the UORLD MEDITSIN company, Great Britain
Rompharm Company of S.R. L., Romania
the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products
of RK, Almaty, Turksibsky district, Suyunbaya Avenue, 222b
Bodies/ph. 8 (7272) 529090 Is made
E-mail address: www.worldmedicine.kz
Related Products
